-
公开(公告)号：US20090312236A1
公开(公告)日：2009-12-17
申请号：US12481111
申请日：2009-06-09
申请人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Doyle , Ryan John Hansen , Shun Li , Sean Shirani , Lianshan Zhang
发明人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Doyle , Ryan John Hansen , Shun Li , Sean Shirani , Lianshan Zhang
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
公开(公告)号：US20110105392A1
公开(公告)日：2011-05-05
申请号：US12997254
申请日：2009-06-09
申请人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Lee Doyle , Ryan John Hansen , Shun Li , Shahriar Shirani , Lianshan Zhang
发明人： John Michael Beals , Gordon Butler Cutler, JR. , Brandon Lee Doyle , Ryan John Hansen , Shun Li , Shahriar Shirani , Lianshan Zhang
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
公开(公告)号：US09050371B2
公开(公告)日：2015-06-09
申请号：US12481111
申请日：2009-06-09
摘要： The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
摘要翻译： 本发明涉及糖尿病领域。 更具体地，本发明涉及用高分子量聚（乙二醇）聚乙二醇化的聚乙二醇化的赖脯胰岛素化合物，在生理pH下是高度可溶的，具有延长的作用持续时间，并且其特征在于药代动力学，药效学和/或活性峰 通过比例小于2.本发明还涉及提供此类分子的方法，含有它们的药物组合物及其治疗用途。
-
公开(公告)号：US20090118190A1
公开(公告)日：2009-05-07
申请号：US12349119
申请日：2009-01-06
申请人： John Michael Beals , Christopher Carl Frye , Wolfgang Glaesner , Shun Li , Radhakrishnan Rathnachalam , Jing Shang , Beth Ann Strifler , Radmila Micanovic
发明人： John Michael Beals , Christopher Carl Frye , Wolfgang Glaesner , Shun Li , Radhakrishnan Rathnachalam , Jing Shang , Beth Ann Strifler , Radmila Micanovic
摘要： The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
摘要翻译： 本发明涉及具有改善的药物性质的人成纤维细胞生长因子21的新颖突变蛋白。 公开了蛋白质和各自编码的核酸物质。 本发明还体现了用于扩增所述核酸序列和产生所述突变蛋白的载体和宿主细胞。 还公开了治疗2型糖尿病，肥胖症，代谢综合征以及降低危重病人死亡率和发病率的方法。
-
公开(公告)号：US07491697B2
公开(公告)日：2009-02-17
申请号：US10579510
申请日：2004-12-01
申请人： John Michael Beals , Christopher Carl Frye , Wolfgang Glaesner , Shun Li , Radhakrishnan Rathnachalam , Jing Shang , Beth Ann Strifler , Radmila Micanovic
发明人： John Michael Beals , Christopher Carl Frye , Wolfgang Glaesner , Shun Li , Radhakrishnan Rathnachalam , Jing Shang , Beth Ann Strifler , Radmila Micanovic
摘要： The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
摘要翻译： 本发明涉及具有改善的药物性质的人成纤维细胞生长因子21的新颖突变蛋白。 公开了蛋白质和各自编码的核酸物质。 本发明还体现了用于扩增所述核酸序列和产生所述突变蛋白的载体和宿主细胞。 还公开了治疗2型糖尿病，肥胖症，代谢综合征以及降低危重病人死亡率和发病率的方法。
-
公开(公告)号：US20080108560A1
公开(公告)日：2008-05-08
申请号：US10506455
申请日：2003-02-21
CPC分类号： C07K14/535 , A61K38/00 , A61K2039/505 , C07K14/765 , C07K2319/00 , C07K2319/30
摘要： The present invention encompasses heterologous fusion 5 proteins comprising a hyperglycsoylated G-CSF analog fused to proteins such as albumin and the Fc portion of animmunoglobulin which act to extend the in vivo half-life of the protein compared to native G-CSF. These fusion proteins are particularly suited for the treatment of conditions 10 treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenital neutropenia.
摘要翻译： 本发明包括异源融合5蛋白，其包含与蛋白质（例如白蛋白）融合的高度糖基化的G-CSF类似物和免疫球蛋白的Fc部分，其与天然G-CSF相比延长了蛋白质的体内半衰期。 这些融合蛋白特别适用于治疗通过刺激循环中性粒细胞（例如化疗方案或慢性先天性中性粒细胞减少症）后可治疗的病症10。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.034 秒)
